Abbott Laboratories

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs carries a market capitalization of 215.23B, placing it among publicly traded companies globally. Its enterprise value stands at 242.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs's next confirmed earnings release is scheduled for January 27, 2027.

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs has 6.52B shares outstanding.

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs trades at a trailing price-to-earnings ratio of 34.25. The price-to-sales ratio is 4.76, and the price-to-book ratio stands at 4.13.

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs trades at an EV/EBITDA multiple of 22.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs trades at an EV/FCF ratio of 31.14, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 242.63B versus a market cap of 215.23B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.60, indicating elevated leverage, while an interest coverage ratio of 20.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs posted a return on equity (ROE) of 12.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.97 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.98, useful for judging operating efficiency across full business cycles. The company generates approximately 394,183.41 in revenue per employee across its workforce of 114,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.90 indicates how many times Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs recorded 1.86B in income tax expense. That works out to an effective tax rate of 22.87, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.14B, leaving 6.28B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs's stock has declined approximately 24.39% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs generated 45.13B in revenue and converted that into 6.28B in net income, yielding earnings per share of 0.96. EBITDA reached 10.87B, while operating income came in at 7.71B.

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs holds 7.30B in cash and equivalents against 34.05B in total debt, resulting in a net debt position of 27.24B. Total book value stands at 52.06B, with working capital of 7.13B providing operational flexibility.

Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs produced 9.46B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.09B in capital expenditures, free cash flow totaled 7.38B - equivalent to 1.13 per share.

Over the twelve months ended March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs posted a gross margin of 56.26, reflecting its pricing power and cost economics. The operating margin of 17.07 and net profit margin of 13.91 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs paid dividends of 0.64 per share. The dividend payout ratio of 66.73 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -6.07, meaning Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs's most recent stock split took place on October 22, 2020 with a 1:2 split ratio.

As of March 31, 2026, Abbott Laboratories Shs Cert Deposito Arg Repr 0.25 Shs has an Altman Z-Score of 4.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.